Sangamo Plunges After Pfizer Ends Pact for Hemophilia Drug - Bloomberg

Sangamo Plunges After Pfizer Ends Pact for Hemophilia Drug  BloombergSangamo selloff on Pfizer decision overdone, says H.C. Wainwright  TipRanksPfizer kills hemophilia gene therapy deal, imperiling Sangamo  STATSangamo Therapeutics to Regain Full Rights to Hemophilia A Gene Therapy Program Following Pfizer’s Decision to Cease Development of Giroctocogene Fitelparvovec  Business Wire